Login to Your Account



Other News To Note


Wednesday, February 20, 2013
• Dompe Group, of Milan, Italy, said the first patient has been enrolled in a Phase I/II REPARO study evaluating the ophthalmological use of a topical solution of recombinant human nerve growth factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription